Brazil - Technology for monoclonal antibodies
A research agency is looking for partners to co-develop innovative immune system improver technology.
You should be able and willing to co-develop and out license immune system improver technology.
It is directed to suppress infections caused by Methicillin-Resistant Staphylococcus Aureus (MRSA).
The technology produces monoclonal antibodies capable of recognising and binding to proteins.
The out licensing can be exclusive or non exclusive.
The co-development can occur in the UK.
Submit your proposal to the Department for International Trade team in Brazil.
All submissions will be reviewed and you will be notified of any potential next steps. You can only submit a proposal if you are a UK registered company.